YIELD10 BIOSCIENCE INC (YTEN) Stock Fundamental Analysis

NASDAQ:YTEN • US98585K8541

2.88 USD
-2.38 (-45.25%)
At close: May 15, 2024
2.89 USD
+0.01 (+0.35%)
After Hours: 5/15/2024, 8:18:42 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to YTEN. YTEN was compared to 520 industry peers in the Biotechnology industry. YTEN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, YTEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • YTEN had negative earnings in the past year.
  • YTEN had a negative operating cash flow in the past year.
  • In the past 5 years YTEN always reported negative net income.
  • YTEN had a negative operating cash flow in each of the past 5 years.
YTEN Yearly Net Income VS EBIT VS OCF VS FCFYTEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

  • The Return On Assets of YTEN (-370.00%) is worse than 96.74% of its industry peers.
Industry RankSector Rank
ROA -370%
ROE N/A
ROIC N/A
ROA(3y)-197.19%
ROA(5y)-147.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
YTEN Yearly ROA, ROE, ROICYTEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

  • YTEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
YTEN Yearly Profit, Operating, Gross MarginsYTEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • YTEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for YTEN has been reduced compared to 1 year ago.
  • Compared to 1 year ago, YTEN has a worse debt to assets ratio.
YTEN Yearly Shares OutstandingYTEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
YTEN Yearly Total Debt VS Total AssetsYTEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

  • YTEN has an Altman-Z score of -157.47. This is a bad value and indicates that YTEN is not financially healthy and even has some risk of bankruptcy.
  • YTEN has a Altman-Z score of -157.47. This is amonst the worse of the industry: YTEN underperforms 98.46% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -157.47
ROIC/WACCN/A
WACC9.13%
YTEN Yearly LT Debt VS Equity VS FCFYTEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

  • A Current Ratio of 0.29 indicates that YTEN may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.29, YTEN is doing worse than 96.57% of the companies in the same industry.
  • YTEN has a Quick Ratio of 0.29. This is a bad value and indicates that YTEN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.29, YTEN is not doing good in the industry: 96.23% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.29
YTEN Yearly Current Assets VS Current LiabilitesYTEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • YTEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1075.36%.
  • YTEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.67%.
  • YTEN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -36.03% yearly.
EPS 1Y (TTM)-1075.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-867.16%
Revenue 1Y (TTM)-86.67%
Revenue growth 3Y-57.83%
Revenue growth 5Y-36.03%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.95% on average over the next years. This is quite good.
  • Based on estimates for the next years, YTEN will show a very strong growth in Revenue. The Revenue will grow by 288.42% on average per year.
EPS Next Y97.63%
EPS Next 2Y40.47%
EPS Next 3Y25.9%
EPS Next 5Y14.95%
Revenue Next Year2712.5%
Revenue Next 2Y607.11%
Revenue Next 3Y594.08%
Revenue Next 5Y288.42%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
YTEN Yearly Revenue VS EstimatesYTEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
YTEN Yearly EPS VS EstimatesYTEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • YTEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year YTEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YTEN Price Earnings VS Forward Price EarningsYTEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YTEN Per share dataYTEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

  • YTEN's earnings are expected to grow with 25.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.47%
EPS Next 3Y25.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for YTEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

YIELD10 BIOSCIENCE INC

NASDAQ:YTEN (5/15/2024, 8:18:42 PM)

After market: 2.89 +0.01 (+0.35%)

2.88

-2.38 (-45.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08
Earnings (Next)08-12
Inst Owners1.81%
Inst Owner Change0%
Ins Owners1.67%
Ins Owner Change0%
Market Cap44.35M
Revenue(TTM)60.00K
Net Income(TTM)-14.46M
Analysts45.71
Price Target12.24 (325%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.51%
Min EPS beat(2)-2.19%
Max EPS beat(2)13.21%
EPS beat(4)1
Avg EPS beat(4)-5.53%
Min EPS beat(4)-17.65%
Max EPS beat(4)13.21%
EPS beat(8)2
Avg EPS beat(8)-4.93%
EPS beat(12)4
Avg EPS beat(12)-2.47%
EPS beat(16)6
Avg EPS beat(16)-1.17%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2300%
PT rev (3m)433.33%
EPS NQ rev (1m)-2300%
EPS NQ rev (3m)-738.09%
EPS NY rev (1m)0%
EPS NY rev (3m)19.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)101.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 739.2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-32.44
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS-0.16
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -370%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-197.19%
ROA(5y)-147.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.86%
Cap/Sales 76.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.29
Quick Ratio 0.29
Altman-Z -157.47
F-Score2
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)53.31%
Cap/Depr(5y)46.87%
Cap/Sales(3y)47.05%
Cap/Sales(5y)31.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1075.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-867.16%
EPS Next Y97.63%
EPS Next 2Y40.47%
EPS Next 3Y25.9%
EPS Next 5Y14.95%
Revenue 1Y (TTM)-86.67%
Revenue growth 3Y-57.83%
Revenue growth 5Y-36.03%
Sales Q2Q%-100%
Revenue Next Year2712.5%
Revenue Next 2Y607.11%
Revenue Next 3Y594.08%
Revenue Next 5Y288.42%
EBIT growth 1Y-7.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.31%
EBIT Next 3Y16.98%
EBIT Next 5Y24.41%
FCF growth 1Y12.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.68%
OCF growth 3YN/A
OCF growth 5YN/A

YIELD10 BIOSCIENCE INC / YTEN FAQ

Can you provide the ChartMill fundamental rating for YIELD10 BIOSCIENCE INC?

ChartMill assigns a fundamental rating of 1 / 10 to YTEN.


Can you provide the valuation status for YIELD10 BIOSCIENCE INC?

ChartMill assigns a valuation rating of 1 / 10 to YIELD10 BIOSCIENCE INC (YTEN). This can be considered as Overvalued.


What is the profitability of YTEN stock?

YIELD10 BIOSCIENCE INC (YTEN) has a profitability rating of 0 / 10.


How financially healthy is YIELD10 BIOSCIENCE INC?

The financial health rating of YIELD10 BIOSCIENCE INC (YTEN) is 0 / 10.


Can you provide the expected EPS growth for YTEN stock?

The Earnings per Share (EPS) of YIELD10 BIOSCIENCE INC (YTEN) is expected to grow by 97.63% in the next year.